

CORCEPT THERAPEUTICS INC
 Form 5
 February 13, 2008

FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0362
 Expires: January 31, 2005
 Estimated average burden hours per response... 1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
 Form 3 Holdings Reported Form 4 Transactions Reported

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
 SINGER DAVID B

(Last) (First) (Middle)

2. Issuer Name and Ticker or Trading Symbol
 CORCEPT THERAPEUTICS INC
 [CORT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
 12/31/2007

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O CORCEPT THERAPEUTICS INCORPORATION, 149 COMMONWEALTH DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Reporting

(check applicable line)

MENLO PARK, CA 94025

(City) (State) (Zip)

Form Filed by One Reporting Person
 Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|------------|-------|--|--|-----------------------------------|
| Common Stock | 12/17/2007 | ^ | G4 | 6,666 | D | \$ 0 | 725,001 | D | ^ |
| Common Stock | 12/17/2007 | ^ | G4 | 6,666 | D | \$ 0 | 718,335 | D | ^ |
| Common Stock | 12/17/2007 | ^ | G4 | 6,666 | D | \$ 0 | 711,669 | D | ^ |
| | ^ | ^ | ^ | ^ | ^ | ^ | 10,166 | I | |

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 5

| | | | | | | | | | | |
|--------------|---|---|---|---|---|---|--------|---|--|--|
| Common Stock | | | | | | | | | | Held by the Singer Kapp Family 2000 Trust Dtd 11/30/00 FBO Elliot Byrd Singer ⁽¹⁾ |
| Common Stock | Â | Â | Â | Â | Â | Â | 6,666 | I | | Held by the Singer Kapp Family 2000 Trust Dtd 11/30/00 FBO Emma S Singer ⁽¹⁾ |
| Common Stock | Â | Â | Â | Â | Â | Â | 50,166 | I | | Held by the Singer Kapp Family 2000 Trust Dtd 11/30/00 FBO Kapp S Singer ⁽¹⁾ |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | | (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| Stock Option | \$ 2.7 | 12/19/2007 | Â | A | 15,000 Â | Â ⁽²⁾ 12/19/2017 | Common Stock 15,000 |

(right to
buy)

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| SINGER DAVID B C/O CORCEPT THERAPEUTICS INCORPORATION 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025 | X | | | |

Signatures

/s/ Joseph K. Belanoff, CEO of
Corcept Therapeutics Incorporated
attorney-in-fact

02/13/2008

Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
- (2) 1/12th of the shares subject to the option vest monthly measured from June 11, 2007, such that 100% of the shares subject to the option will be fully vested and exercisable on June 11, 2008

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.